Business context and reporting period
NeuroOne Medical Technologies Corporation is an early-stage medical-device company developing and commercializing thin-film brain electrodes and related technologies. This Form 10-Q reports fiscal third-quarter and nine-month results for periods ended June 30, 2023, compared with the same periods in 2022. The company had FDA 510(k) clearance for its cortical electrodes and, since October 2022, its sEEG electrodes; it reported limited commercial sales.
Key financial metrics
| Metric | Three months ended June 30 | Nine months ended June 30 |
|---|---|---|
| Product revenue | 2023: $629,906; 2022: $32,049 | 2023: $1,210,661; 2022: $102,381 |
| Collaboration revenue | 2023: $0; 2022: $0 | 2023: $1,455,188; 2022: $6,374 |
| Product gross profit (loss) | 2023: $243,666; 2022: $(6,413) | 2023: $262,862; 2022: $(55,732) |
| Operating expenses | 2023: $3,753,901; 2022: $2,755,021 | 2023: $10,508,556; 2022: $8,581,211 |
| Net loss | 2023: $(3,468,773); 2022: $(2,759,727) | 2023: $(8,724,370); 2022: $(8,625,269) |
| Operating cash flow | Not separately presented | 2023: $(9,984,048); 2022: $(8,537,351) |
Product gross margin was approximately 38.7% for the quarter and 21.7% for the nine-month period in 2023. These are calculated from reported product revenue and product gross profit and exclude collaboration revenue.
At June 30, 2023, cash and cash equivalents were $3.08 million, with no short-term investments; current assets were $4.88 million and current liabilities $1.75 million. Total liabilities were $1.84 million, including operating lease liabilities; the filing reports no borrowings. Accumulated deficit was $59.55 million. Nine-month investing cash flow was positive $2.70 million, primarily reflecting investment maturities, and financing cash flow was positive $2.21 million, mainly from ATM share sales. Cash declined $5.08 million over the nine months.
Material changes versus prior comparable periods
- Quarterly product revenue rose by about $598,000 and nine-month product revenue by about $1.11 million. Management attributed improved product gross profit mainly to higher sales volume spreading fixed royalty costs.
- Nine-month collaboration revenue included $1.46 million recognized after the sEEG exclusivity-maintenance performance obligation was completed following FDA clearance. No collaboration revenue was recognized in the 2023 quarter.
- Operating expenses increased $999,000 for the quarter and $1.93 million for the nine months. Research and development drove most of the nine-month increase, rising $1.67 million, principally for sEEG development.
- Quarterly net loss widened by $709,000; nine-month net loss increased by $99,101. Operating cash use increased by about $1.45 million year over year.
- Cash and cash equivalents fell from $8.16 million at September 30, 2022 to $3.08 million at June 30, 2023. Inventory increased from $705,000 to $1.52 million.
Outlook, risks and unusual items
- Going concern and financing: The company has recurring losses and negative operating cash flow, and management says substantial doubt exists about its ability to continue as a going concern. A July 2023 public offering of 6,037,500 shares generated approximately $5.21 million net proceeds. The filing says the offering provides liquidity to fund operations through March 31, 2024; further capital may be needed, and planned spending could be reduced if funding or expected results do not materialize.
- Development and commercialization: NeuroOne launched its Evo sEEG product line with exclusive distributor Zimmer Biomet in May 2023. It submitted a 510(k) application for the OneRF ablation system in June 2023. The company expects research, development and commercialization expenses to increase; no quantified revenue or earnings guidance is provided.
- Concentration and execution: One customer accounted for all product and collaboration revenue, and one contract manufacturer produced all Strip/Grid and sEEG products. Zimmer has exclusive distribution rights; delays or failure to commercialize could materially harm results.
- Fraud and controls: A January 2023 business-email-compromise fraud caused an approximately $100,000 loss. The company is pursuing recovery but does not know whether it will recover the funds. Management reported disclosure controls were not effective due to a material weakness in verification of vendor wire payments; remediation procedures were introduced, but effectiveness is not assured.
- Other risks and contingencies: Product adoption, regulatory approvals, reimbursement, manufacturing performance, access to capital, macroeconomic conditions and intellectual-property obligations remain risks. No material loss contingency or material litigation was reported. WARF royalties include minimum annual payments of $150,000 for 2022 and each subsequent calendar year while the license remains in effect.
- Financing and dilution: The company issued shares under its ATM program during the period and completed the July offering after quarter-end. Common shares outstanding were 23,919,184 as of August 10, 2023.
Important facts for investors to verify
- Whether post-offering cash and operating results support management’s stated runway through March 31, 2024, and when additional financing may be required.
- Whether sEEG sales through Zimmer Biomet grow beyond initial launch shipments and reduce customer concentration.
- The status and timing of FDA review of the OneRF 510(k) submission and the resources needed to advance other development programs.
- Whether the wire-fraud funds are recovered and whether the material weakness is remediated and controls are operating effectively.
- The extent of future share issuance, including ATM activity, equity awards and related dilution.